Leerink Partners Initiates Coverage On Scribe Therapeutics with Outperform Rating, Announces Price Target of $37
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Leerink Partners analyst David Risinger initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Outperform rating and announces Price Target of $37.
Leerink Partners analyst David Risinger initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Outperform rating and announces Price Target of $37.